Clinical trials: Diabetes Type 2
Diabetes Mellitus
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2…
- Trial name
- NCT02229396
- Testing
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Where
- 133 sites in United States, Hungary and 4 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Obesity, Cardiovascular Risk Factor
Coordinating Pragmatic Primary Care Population Management for Obesity
The C3PO pilot and feasibility study uses a rigorous, mixed-method research design to provide information needed to refine and implement a technology-mediated primary care outreach intervention approach before conducting a larger…
- Trial name
- C3PO (NCT03998046)
- Testing
- Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Northwestern University
Type 2 Diabetes, Hypertension
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
To assess the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by…
- Trial name
- NCT02796170
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Tulane University School of Medicine
Type 2 Diabetes
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1
The objective of this protocol is to answer the questions: 1) Are financial incentives layered upon nurse education and home telemonitoring superior to nurse education and home telemonitoring alone in improving metabolic control…
- Trial name
- FINANCE-DM (NCT04203173)
- Testing
- FINANCE-DM, Active Comparator
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- State University of New York at Buffalo
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Hypogonadism in Young Men With Type 2 Diabetes
Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men.
- Trial name
- NCT01155518
- Testing
- testosterone, clomiphene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- State University of New York at Buffalo
Diabetes Mellitus, Type 2
QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
QR-Bromocriptine as an add-on treatment to insulin and metformin in the management of type 2 diabetes will result in improved glycemic control, reduced exogenous insulin requirement, increased lean fat mass and improved…
- Trial name
- NCT01474018
- Testing
- QR-bromocriptine
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Obesity, Overweight
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 2 (NCT03552757)
- Testing
- Semaglutide 1.0 mg, Semaglutide 2.4 mg
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 1,210 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
The investigators hypothesize that the impaired insulinotropic effect of the incretin hormone GIP may be due to inadequate sensitization and ATP induced closure of beta cell K-ATP channels.
- Trial name
- NCT00321321
- Testing
- Sulfonylurea
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or…
- Trial name
- NCT01664247
- Testing
- insulin degludec, liraglutide
- Where
- 132 sites in United States, Canada and 9 more
- Volunteers
- 346 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
The purpose of this study is to observe alogliptin and alogliptin fixed-dose combinations (FDCs) utilization patterns, as well as clinical response to treatment with alogliptin or alogliptin FDCs, in standard clinical practice.
- Trial name
- NCT02989649
- Testing
- Alogliptin, Alogliptin FDC With Pioglitazone, Alogliptin FDC With Metformin
- Where
- 11 sites in China, Hong Kong
- Volunteers
- 593 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
- Trial name
- AM7D (NCT01023581)
- Testing
- Alogliptin, Metformin
- Where
- 201 sites in United States, Czechia and 11 more
- Volunteers
- 784 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus (T2DM)
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
- Trial name
- NCT01514149
- Testing
- CJC-1134-PC Injection
- Where
- 22 sites in United States, Canada
- Volunteers
- 73 people
- Sponsor
- ConjuChem
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01373450
- Testing
- Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
- Trial name
- NCT01834274
- Testing
- Fasiglifam (TAK-875), Sitagliptin, Metformin
- Where
- 104 sites in United States, Argentina and 11 more
- Volunteers
- 96 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
This trial will assess the safety and efficacy of omarigliptin (MK-3102) compared with the sulfonylurea, glimepiride, in type 2 diabetes mellitus participants who are metformin intolerant or who have a contraindication to the use…
- Trial name
- NCT01863667
- Testing
- Omarigliptin, Glimepiride
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC